Rapid Activity of Platelet Inhibitor Drugs Study 2

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions
Myocardial Infarction
Interventions
DRUG

Prasugrel

25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .

DRUG

Ticagrelor

25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .

Trial Locations (1)

Unknown

Careggi Hospital, Florence

All Listed Sponsors
collaborator

A.R. CARD Onlus Foundation

OTHER

lead

David Antoniucci

OTHER

NCT01805570 - Rapid Activity of Platelet Inhibitor Drugs Study 2 | Biotech Hunter | Biotech Hunter